• Mutation; VGNC; VGNC:84862; EP300; Simple; p.Asn1570fs (c.4704dupG); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:44555; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); Zygosity=Homozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:47719; TP53; Simple; p.Ala150fs (c.447delG); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; VGNC:47719; TP53; Simple; p.Leu184Phe (c.550C>T); Zygosity=Heterozygous (PubMed=31175136).
  

PubMed=15064773; DOI=10.1038/labinvest.3700080
Fosmire S.P., Dickerson E.B., Scott A.M., Bianco S.R., Pettengill M.J., Meylemans H.A., Padilla M.L., Frazer-Abel A.A., Akhtar N., Getzy D.M., Wojcieszyn J., Breen M., Helfand S.C., Modiano J.F.
Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium.
Lab. Invest. 84:562-572(2004)

PubMed=15140399; DOI=10.1593/neo.03334; PMCID=PMC1502086
Akhtar N., Padilla M.L., Dickerson E.B., Steinberg H., Breen M., Auerbach R., Helfand S.C.
Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model.
Neoplasia 6:106-116(2004)

PubMed=22594682; DOI=10.1111/j.1476-5829.2012.00335.x
Lyles S.E., Milner R.J., Kow K., Salute M.E.
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Vet. Comp. Oncol. 10:223-235(2012)

PubMed=24582862; DOI=10.1016/j.yexcr.2014.02.020; PMCID=PMC4256199
Kim J.-H., Frantz A.M., Anderson K.L., Graef A.J., Scott M.C., Robinson S., Sharkey L.C., O'Brien T.D., Dickerson E.B., Modiano J.F.
Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.
Exp. Cell Res. 323:155-164(2014)

PubMed=25190452; DOI=10.1186/s12917-014-0184-9; PMCID=PMC4172958
Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.
The long-acting COX-2 inhibitor mavacoxib (Trocoxil TM) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro.
BMC Vet. Res. 10:184.1-184.11(2014)

PubMed=26842912; DOI=10.1111/vco.12197
Hartley G., Faulhaber E.A., Caldwell A., Coy J., Kurihara J.N., Guth A., Regan D.P., Dow S.W.
Immune regulation of canine tumour and macrophage PD-L1 expression.
Vet. Comp. Oncol. 15:534-549(2017)

PubMed=28029283; DOI=10.2460/ajvr.78.1.69; PMCID=PMC5299388
Witter L.E., Gruber E.J., Lean F.Z.-X., Stokol T.
Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines.
Am. J. Vet. Res. 78:69-79(2017)

PubMed=30601866; DOI=10.1371/journal.pone.0210297; PMCID=PMC6314605
Dowling M., Samuelson J., Fadl-Alla B.A., Pondenis H.C., Byrum M., Barger A.M., Fan T.M.
Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.
PLoS ONE 14:E0210297-E0210297(2019)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)